Filing Details
- Accession Number:
- 0001104659-11-065789
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-11-22 16:07:30
- Reporting Period:
- 2011-11-22
- Filing Date:
- 2011-11-22
- Accepted Time:
- 2011-11-22 16:07:30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1093649 | Idenix Pharmaceuticals Inc | IDIX | Pharmaceutical Preparations (2834) | 450478605 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1030617 | Ag Pharma Novartis | Lichstrasse 35 Basel V8 CH4002 | No | No | Yes | No | |
| 1114448 | Ag Novartis | Lichstrasse 35 Basel V8 CH4002 | No | No | No | Yes |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2011-11-22 | 11,236 | $2.41 | 33,196,427 | No | 4 | P | Indirect | See footnote |
| Common Stock | Acquisiton | 2011-11-22 | 6,476 | $2.95 | 33,202,903 | No | 4 | P | Indirect | See footnote |
| Common Stock | Acquisiton | 2011-11-22 | 1,146 | $3.17 | 33,204,049 | No | 4 | P | Indirect | See footnote |
| Common Stock | Acquisiton | 2011-11-22 | 140 | $3.79 | 33,204,189 | No | 4 | P | Indirect | See footnote |
| Common Stock | Acquisiton | 2011-11-22 | 20,228 | $4.70 | 33,224,477 | No | 4 | P | Indirect | See footnote |
| Common Stock | Acquisiton | 2011-11-22 | 2,107 | $5.11 | 33,226,584 | No | 4 | P | Indirect | See footnote |
| Common Stock | Acquisiton | 2011-11-22 | 9,197 | $5.46 | 33,235,781 | No | 4 | P | Indirect | See footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | See footnote |
| No | 4 | P | Indirect | See footnote |
| No | 4 | P | Indirect | See footnote |
| No | 4 | P | Indirect | See footnote |
| No | 4 | P | Indirect | See footnote |
| No | 4 | P | Indirect | See footnote |
| No | 4 | P | Indirect | See footnote |
Footnotes
- These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is an indirect beneficial owner of these securities. See attachment.
Billionaire Hedge Funds
